Uses of Liraglutide

Liraglutide, marketed under the brand names Victoza and Saxenda, is a glucagon-like peptide-1 (GLP-1) receptor agonist. This innovative drug has proven to be highly effective in the management of type 2 diabetes mellitus, obesity, and other related conditions. Common side effects include nausea, low blood sugar, dizziness, abdominal pain, and pain at the site of injection.

Browse all Liraglutide products

Medical Uses of Liraglutide

Liraglutide plays a crucial role in improving blood glucose control. Studies have demonstrated its effectiveness in reducing the risk of cardiovascular events, such as cardiovascular-related deaths, nonfatal myocardial infarction, and nonfatal stroke, particularly in patients with high cardiovascular risk. The American Diabetes Association (ADA) guidelines now consider liraglutide as first-line pharmacologic therapy for type 2 diabetes, often in combination with metformin. This recommendation is especially relevant for patients with atherosclerotic cardiovascular disease or obesity.

Liraglutide has also shown promising results in the management of obesity. In combination with lifestyle modifications, Liraglutide aids weight loss by suppressing appetite, increasing satiety, and reducing food intake. The drug acts on the hypothalamus, regulating hunger signals and promoting a feeling of fullness. Clinical studies have revealed that treatment with Liraglutide leads to significant weight reduction, improved body composition, and a reduced risk of obesity-related complications

Detection Methods for Liraglutide

Pharmaceutical companies are increasingly focusing on developing liraglutide analogs and new GLP-1 receptor agonists. To facilitate liraglutide applications and accelerate the development of novel GLP-1 receptor agonists, the establishment of a highly efficient analytical platform is crucial. Such a platform should be simple, robust, and capable of high-throughput analysis.

In 2002, Agerso pioneered the use of an enzyme-linked immunosorbent assay (ELISA) method to quantify liraglutide in a pharmacokinetics (PK) study. Since then, the ELISA method has gained widespread recognition and has become the standard approach for determining liraglutide levels in PK studies. Ligand binding assays (LBAs), including ELISA and RIA, have long been considered the classical method for quantitative analysis of peptides and proteins. These methods typically offer high sensitivity and applicability to a wide range of peptides and proteins. However, as liquid chromatography-mass spectrometry (LC-MS) has advanced, the limitations of LBAs have become more apparent. These limitations include time-consuming and costly method development, variability of critical reagents, limited transferability to different matrices/species, and the infeasibility of simultaneous quantification.

LC-MS/MS methods have traditionally been used for robust bioanalytical support in drug exposure studies. However, peptides and proteins present challenges for LC-MS/MS analysis due to poor ionization, endogenous interference, and low concentrations. In recent years, LC-MS/MS methods have emerged as a promising alternative to LBAs for studying peptides and proteins. This is made possible by employing biological sample preprocessing techniques such as enzyme digestion and immune purification. The process involves hydrolyzing peptides and proteins into multiple smaller molecular weight peptides, from which a specific peptide is selected for quantification. This indirect measurement approach allows for achieving sensitivity similar to LBAs while offering enhanced specificity and minimizing cross-reactions. However, the increased complexity of sample preprocessing makes high-throughput applications difficult to achieve.

Liraglutide-Related Antibodies

Liraglutide-Related Antigens

Liraglutide-Related ELISA Kits